Clinical trial
The Efficacy and Safety of Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in the Treatment of Relapsed or Refractory Natural Killer / T-cell Lymphoma
NCT06573138 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in the Treatment of Relapsed or Refractory Natural Killer / T-cell Lymphoma
- Lead sponsor
- Ruijin Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 1, 2024
- Completion date
- July 1, 2027
- Enrollment
- 18 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.